Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21207640 | 0.81 | SSTR4 (0.38) | SSTR4CCR1RAB9ACCR5 | |
| SCHEMBL11955219 | 0.78 | SSTR4 (0.41) | SSTR4CCR1RAB9ACCR5KDM4E | |
| SCHEMBL24198889 | 0.77 | APOBEC3A (0.41) | CCR1RAB9ACCR5KDM4EALDH1A1 | |
| SCHEMBL26354510 | 0.74 | ALDH1A1 (0.46) | RAB9AKDM4EALDH1A1 | |
| SCHEMBL3231080 | 0.74 | SSTR4 (0.40) | SSTR4CCR1RAB9ACCR5KDM4E | |
| SCHEMBL19687547 | 0.72 | SSTR4 (0.35) | SSTR4 | |
| SCHEMBL13865687 | 0.71 | RAB9A (0.39) | SSTR4CCR1RAB9ACCR5ALDH1A1 | |
| SCHEMBL13463113 | 0.71 | SSTR4 (0.48) | SSTR4CCR1RAB9ACCR5CYP1A2 | |
| SCHEMBL3741710 | 0.71 | SSTR4 (0.39) | SSTR4KDM4EALDH1A1 | |
| SCHEMBL22547851 | 0.70 | SSTR4 (0.35) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | SSTR4 1683/4885CCR1 1959/4885RAB9A 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.